Selected research
Industry Research
Antimycobacterial Drugs Industry Research Report 2026
Market perspective
The global Antimycobacterial Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antimycobacterial Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antimycobacterial Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antimycobacterial Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antimycobacterial Drugs include Sanofi, Novartis, Merck, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Zydus Cadila and Systopic Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antimycobacterial Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antimycobacterial Drugs Market by Company
Sanofi
Novartis
Merck
Pfizer
GlaxoSmithKline
Bayer
AstraZeneca
Zydus Cadila
Systopic Laboratories
Macleods Pharmaceuticals
Lupin
Antimycobacterial Drugs Segment by Type
Drugs Used for Tuberculosis
Drugs Used for Leprosy
Drugs Used for Atypical Mycobacteria
Antimycobacterial Drugs Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Antimycobacterial Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antimycobacterial Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antimycobacterial Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antimycobacterial Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antimycobacterial Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antimycobacterial Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antimycobacterial Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drugs Used for Tuberculosis
- Drugs Used for Leprosy
- Drugs Used for Atypical Mycobacteria
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Sanofi
- Novartis
- Merck
- Pfizer
- GlaxoSmithKline
- Bayer
- AstraZeneca
- Zydus Cadila
- Systopic Laboratories
- Macleods Pharmaceuticals
- Lupin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antimycobacterial Drugs Market Size (2021-2032)
- 2.2.2 Global Antimycobacterial Drugs Sales (2021-2032)
- 2.2.3 Global Antimycobacterial Drugs Market Average Price (2021-2032)
- 2.3 Antimycobacterial Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Drugs Used for Tuberculosis
- 2.3.3 Drugs Used for Leprosy
- 2.3.4 Drugs Used for Atypical Mycobacteria
- 2.4 Antimycobacterial Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Hospital Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antimycobacterial Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antimycobacterial Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antimycobacterial Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Antimycobacterial Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Antimycobacterial Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antimycobacterial Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antimycobacterial Drugs, Product Type & Application
- 3.8 Global Manufacturers of Antimycobacterial Drugs, Established Date
- 3.9 Global Antimycobacterial Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Antimycobacterial Drugs Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Antimycobacterial Drugs Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Antimycobacterial Drugs Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Antimycobacterial Drugs Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Antimycobacterial Drugs Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Antimycobacterial Drugs Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Antimycobacterial Drugs Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
- 4.8 Zydus Cadila
- 4.8.1 Zydus Cadila Company Information
- 4.8.2 Zydus Cadila Business Overview
- 4.8.3 Zydus Cadila Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zydus Cadila Antimycobacterial Drugs Product Portfolio
- 4.8.5 Zydus Cadila Recent Developments
- 4.9 Systopic Laboratories
- 4.9.1 Systopic Laboratories Company Information
- 4.9.2 Systopic Laboratories Business Overview
- 4.9.3 Systopic Laboratories Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Systopic Laboratories Antimycobacterial Drugs Product Portfolio
- 4.9.5 Systopic Laboratories Recent Developments
- 4.10 Macleods Pharmaceuticals
- 4.10.1 Macleods Pharmaceuticals Company Information
- 4.10.2 Macleods Pharmaceuticals Business Overview
- 4.10.3 Macleods Pharmaceuticals Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Macleods Pharmaceuticals Antimycobacterial Drugs Product Portfolio
- 4.10.5 Macleods Pharmaceuticals Recent Developments
- 4.11 Lupin
- 4.11.1 Lupin Company Information
- 4.11.2 Lupin Business Overview
- 4.11.3 Lupin Antimycobacterial Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Lupin Antimycobacterial Drugs Product Portfolio
- 4.11.5 Lupin Recent Developments
5 Global Antimycobacterial Drugs Market Scenario by Region
- 5.1 Global Antimycobacterial Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antimycobacterial Drugs Sales by Region: 2021-2032
- 5.2.1 Global Antimycobacterial Drugs Sales by Region: 2021-2026
- 5.2.2 Global Antimycobacterial Drugs Sales by Region: 2027-2032
- 5.3 Global Antimycobacterial Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Antimycobacterial Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Antimycobacterial Drugs Revenue by Region: 2027-2032
- 5.4 North America Antimycobacterial Drugs Market Facts & Figures by Country
- 5.4.1 North America Antimycobacterial Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antimycobacterial Drugs Sales by Country (2021-2032)
- 5.4.3 North America Antimycobacterial Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Antimycobacterial Drugs Market Facts & Figures by Country
- 5.5.1 Europe Antimycobacterial Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antimycobacterial Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Antimycobacterial Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Antimycobacterial Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antimycobacterial Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antimycobacterial Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antimycobacterial Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antimycobacterial Drugs Market Facts & Figures by Country
- 5.7.1 South America Antimycobacterial Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antimycobacterial Drugs Sales by Country (2021-2032)
- 5.7.3 South America Antimycobacterial Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Antimycobacterial Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antimycobacterial Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antimycobacterial Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antimycobacterial Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Antimycobacterial Drugs Sales by Type (2021-2032)
- 6.1.1 Global Antimycobacterial Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antimycobacterial Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Antimycobacterial Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Antimycobacterial Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antimycobacterial Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Antimycobacterial Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antimycobacterial Drugs Sales by Application (2021-2032)
- 7.1.1 Global Antimycobacterial Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antimycobacterial Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Antimycobacterial Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Antimycobacterial Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antimycobacterial Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Antimycobacterial Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antimycobacterial Drugs Value Chain Analysis
- 8.1.1 Antimycobacterial Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antimycobacterial Drugs Production Mode & Process
- 8.2 Antimycobacterial Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antimycobacterial Drugs Distributors
- 8.2.3 Antimycobacterial Drugs Customers
9 Global Antimycobacterial Drugs Analyzing Market Dynamics
- 9.1 Antimycobacterial Drugs Industry Trends
- 9.2 Antimycobacterial Drugs Industry Drivers
- 9.3 Antimycobacterial Drugs Industry Opportunities and Challenges
- 9.4 Antimycobacterial Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst